Daniel Leventhal, MS, PhD, Head of Immunogenicity, will present on new machine learning approaches to predict and mitigate immunogenicity risk at the Cambridge Healthtech Institute Bioassay and Immunogenicity Summit on October 4. Dan will speak broadly about the kinds of predictive and generative models that are used in protein design. He will also demonstrate how these techniques can be applied to co-optimize amongst multiple critical drug quality attributes (like immunogenicity and developability) early in the discovery process. Learn more: https://lnkd.in/e-uedXaN #ProteinEngineering I #MachineLearning